Nationwide alert in China for the faulty rabies vaccine

The second largest drug manufacturing company “ Changchun Changsheng Life Sciences” were found guilty for violated national standards including usage of expired fluids and falsified production dates to produce rabies vaccine. Rabies Vaccines manufactured in China was widely exported to countries including India too.

This recent scandal of faulty Rabies Vaccines creating panic and especially in China. After taking a quick action on this, country has started a nationwide campaign to provide health consultation and free inoculation of rabies vaccines.

In India, the Drug Controller General of India also ordered immediately to withdraw rabies vaccines from the market and also banned their imports from Changchun Changsheng Life Sciences.

Healthcare centers, institutions and disease control centers have started providing consultation services for those who received or used rabies vaccines made by the company. 36,482 hospitals and health centers are designated by the China government to provide consultation. No life loss has been reported yet from the patients who injected with the faulty Rabies vaccines.

According to the report, Changchun Changsheng making use of expired fluids and false production dates is in continuity since April 2014 and had violated rules on production management and national drug standards for the vaccines.

China National Health Commission and the State Drug Administration are actively working on the issue and created an inoculation plan for patients who have injected rabies vaccines from the Changchun Changsheng company. And the patients who are getting treated and those whose required course are not yet completed can switch to vaccines from other companies at no charge.

China government also start giving free re-inoculated who have completed their courses less than a year ago and vaccination institutions will provide tracking, observation, and advisory services.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit